BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12956425)

  • 1. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
    Krol J; Sato S; Rettenberger P; Assfalg-Machleidt I; Schmitt M; Magdolen V; Magdolen U
    Biol Chem; 2003 Jul; 384(7):1085-96. PubMed ID: 12956425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
    Krol J; Kopitz C; Kirschenhofer A; Schmitt M; Magdolen U; Krüger A; Magdolen V
    Biol Chem; 2003 Jul; 384(7):1097-102. PubMed ID: 12956426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
    Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V
    Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
    Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
    Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
    Muehlenweg B; Assfalg-Machleidt I; Parrado SG; Bürgle M; Creutzburg S; Schmitt M; Auerswald EA; Machleidt W; Magdolen V
    J Biol Chem; 2000 Oct; 275(43):33562-6. PubMed ID: 10913110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
    Tan X; Egami H; Nozawa F; Abe M; Baba H
    Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
    Ramer R; Hinz B
    J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
    Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ
    Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
    Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
    J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
    Choong PF; Nadesapillai AP
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effect of MT1-MMP antisense nucleotide on invasion of human highly metastatic ovarian cancer cell line SW626].
    Wu MF; Liao GN; Jia P; Xi L; Lu YP; Ma D
    Ai Zheng; 2004 Nov; 23(11):1263-6. PubMed ID: 15522170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3.
    Tran PL; Vigneron JP; Pericat D; Dubois S; Cazals D; Hervy M; DeClerck YA; Degott C; Auclair C
    Cancer Gene Ther; 2003 Jun; 10(6):435-44. PubMed ID: 12768188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.